Indivior (NASDAQ:INDV) Insider Christian Heidbreder Sells 18,586 Shares of Stock

Indivior PLC (NASDAQ:INDV) insider Christian Heidbreder sold 18,586 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the sale, the insider directly owned 209,337 shares in the company, valued at $8,612,124.18. This trade represents a 8.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Indivior Stock Performance

NASDAQ INDV opened at $40.21 on Tuesday. Indivior PLC has a one year low of $15.00 and a one year high of $42.81. The company has a 50-day simple moving average of $38.59 and a 200-day simple moving average of $35.04. The firm has a market capitalization of $4.90 billion, a PE ratio of 20.62 and a beta of 0.86.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. The business had revenue of $317.00 million during the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. Equities analysts forecast that Indivior PLC will post 4.05 earnings per share for the current year.

Institutional Investors Weigh In On Indivior

Large investors have recently made changes to their positions in the company. Quarry LP acquired a new position in shares of Indivior during the third quarter worth approximately $26,000. Raymond James Financial Inc. acquired a new stake in Indivior in the 2nd quarter valued at approximately $26,000. Salomon & Ludwin LLC acquired a new stake in Indivior in the 4th quarter valued at approximately $30,000. Harbor Capital Advisors Inc. raised its stake in Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on INDV shares. Weiss Ratings cut Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Barclays started coverage on Indivior in a research report on Thursday, June 18th. They set an “overweight” rating and a $46.00 price objective for the company. Finally, Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Indivior has an average rating of “Moderate Buy” and a consensus target price of $40.29.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.